北美紫杉烷市场，按类型（紫杉醇、多西他赛、卡巴他赛）、药物类型（仿制药、品牌药）、剂型（脂质体、纳米颗粒、聚合物胶束、其他）、年龄组（成人、老年人）、应用（乳腺癌、非小细胞肺癌、胰腺癌、卵巢癌、前列腺癌、其他）、最终用户（医院、门诊手术中心、专科诊所、其他）分销渠道（零售、直接招标）划分 - 行业趋势和预测到 2029 年。
市场分析和见解
预计北美紫杉烷市场将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 7.7%。紫杉烷药物治疗的技术进步，加上计算机辅助诊断应用的不断增加，是推动预测期内紫杉烷市场增长的其他因素。
然而，药物的高成本以及血栓、白细胞减少、过敏、腹泻和体重减轻等副作用将抑制市场的增长。主要市场参与者建立合作伙伴关系和收购等战略联盟是紫杉烷市场增长的机会。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
按类型（紫杉醇、多西他赛和卡巴他赛）、药品类型（品牌药和仿制药）、剂型（含紫杉烷的脂质体和聚合物胶束、紫杉烷的水凝胶剂型、纳米颗粒剂型等）、年龄组（成人和老年人）、应用（卵巢癌、乳腺癌、前列腺癌、非小细胞肺癌等）、最终用户（医院、门诊手术中心、专科诊所等）、分销渠道（直接招标、零售） |
|
覆盖国家 |
美国、加拿大、墨西哥 |
|
涵盖的市场参与者 |
Viatris Inc.、Sandoz International GmbH（诺华公司旗下的一个部门）、sanofi-aventis US LLC、Hikma Pharmaceuticals PLC、辉瑞公司、Dr. Reddy's Laboratories Ltd.、Taxane Healthcare、百时美施贵宝公司、Fresenius Kabi AG（Fresenius SE & Co. KGaA 的子公司）、三阳控股株式会社、绿叶制药集团、Elevar Therapeutics、辉昂药业股份有限公司、深圳万乐药业有限公司、Accord Healthcare、Torrent Pharmaceuticals Ltd.、Panacea Biotec、RPG Life Sciences Limited.、Aureate Healthcare、Samarth Life Sciences Pvt. Ltd.、Cipla Inc.、Hetero Healthcare Limited.、AqVida GmbH、Ingenus Pharmaceuticals, LLC 等等。 |
紫杉烷市场定义
紫杉烷或紫杉醇类是一类密切相关的抗肿瘤药物，具有作为有丝分裂抑制剂的独特作用机制，广泛用于治疗卵巢癌、乳腺癌、肺癌、食道癌、前列腺癌、膀胱癌和头颈癌。临床上使用的紫杉烷有三种，即紫杉醇 (Taxol：1992 年)、多西他赛 (Taxotere：1996 年) 和卡巴他赛 (Jevtana：2010 年)。紫杉烷是干扰微管功能，导致有丝分裂改变和细胞死亡的抗癌药物。紫杉醇 (Taxol) 最早是从紫杉树中分离出来的，紫杉树是一种生长速度缓慢的小型常绿针叶树。由于紫杉醇最初很稀缺，因此人们从欧洲紫杉树 Taxus baccata 的针叶中提取了紫杉醇的半合成类似物多西他赛 (Taxotere)。多西他赛与紫杉醇在两个化学位置上有所不同，这使得它更易溶于水。卡巴他赛也是天然紫杉醇的半合成类似物，因其对 P-糖蛋白（多西他赛耐药性的常见介质）缺乏亲和力而被开发出来。
此外，由于慢性病发病率上升、癌症发病率飙升以及医疗基础设施投资增加，紫杉烷类药物的使用量不断增加。这些因素增加了紫杉烷类市场的需求，并鼓励主要市场参与者通过产品发布、收购、战略和协议来实施新技术和战略。
紫杉烷市场动态
驱动程序
- 癌症发病率上升
癌症对美国和全世界的社会产生了重大影响。癌症统计数据描述了大群体中发生的情况，并及时描绘出癌症对社会造成的负担。紫杉醇是一种用于治疗癌症的抗有丝分裂剂，它通过阻止细胞分裂来阻止癌细胞生长，从而导致细胞死亡。
据美国国家癌症研究所 (NCI) 称，一项由政府资助的临床试验发现，30% 的晚期卵巢癌患者对紫杉烷治疗反应良好。在临床实践中，紫杉烷现在是转移性乳腺癌的标准疗法。如今，紫杉醇已被列入世界卫生组织的基本药物标准清单，是一种可以杀死癌细胞的细胞毒性药物。它可以治疗乳腺癌、卵巢癌、非小细胞肺癌、胰腺癌和艾滋病相关的卡波西肉瘤。
- 政府的资助和研发的投资
尽管药物疗法在治疗阿片类药物滥用和酒精成瘾方面已得到证实，但人们发现，紫杉烷在专科治疗计划中的应用存在局限性。需要特别注意资金、组织结构和人力资源的具体来源，进行长期投资，使资金支付与未来的潜在受益者保持一致。药物开发的可持续性、生产力和患者影响问题从来都不是、也不会仅仅是行业的产物。
政府的资助将确保患者的安全，节省医疗费用。此外，医院和医疗机构将通过与政府机构合作，以较低的价格实施这种治疗。因此，研发活动的进步和政府的资助预计将推动市场增长。
克制
-
紫杉烷类药物的副作用
紫杉烷属于二萜类。紫杉烷类药物（紫杉醇和多西他赛）用作化疗药物。由于正在进行的临床试验、研究、癌症类型、治疗方案类型和药物剂量，目前的高成本预计未来将呈下降趋势。紫杉烷类药物对治疗乳腺癌和前列腺癌最有效。然而，已报告某些副作用。报告的不良并发症或副作用将导致紫杉烷类药物销量下降，从而限制药物的销量。此外，它还会影响参与该市场的制造商的可靠性，因此预计会抑制市场增长。
机会
-
市场参与者的战略主动性
由于及时治疗酒精和阿片类药物障碍，美国和欧洲对紫杉烷市场的需求有所增加。这些有利因素增加了对紫杉烷的需求，为了满足市场需求，大大小小的市场参与者都在采用各种策略。
主要参与者还试图制定具体的策略，例如产品发布、收购、批准、扩张和合作，以确保业务顺利进行，避免风险，并增加市场销售的长期增长。
市场参与者的这些战略举措，包括收购、会议和重点细分产品发布，正在帮助公司发展并改善公司的产品组合，最终带来更多收入。因此，市场参与者的这些战略举措为未来增长和推动市场增长提供了机会。
挑战
- 缺乏紫杉类药物治疗所需的熟练专业人员
缺乏或短缺专业技能将影响一个地方的复苏和增长速度。一个地方的失业者往往拥有其他地方所缺乏的技能。此外，该领域的快速技术进步也导致缺乏专业知识。
医生供应量是一个术语，用于描述在医疗保健系统或劳动力市场中工作的受过培训的医生的数量。它取决于毕业生的数量和该专业的留任率。医生短缺是全球许多国家日益关注的问题。
世界卫生组织 (WHO) 估计，全球医生、护士和其他卫生专业人员的缺口为 430 万。尽管有强有力的证据表明药物在降低发病率和死亡率、增加治疗保留率和改善紫杉烷类药物患者健康状况方面有效，但众多障碍阻碍了更广泛地获得紫杉烷类药物治疗。
此外，技术进步是导致对熟练专业人员需求增加的另一个方面。神经科医生报告称，他们的中心存在大量未满足的支持性护理需求和障碍，只有少数人认为自己有能力提供支持性护理。迫切需要对治疗痴呆症的专业人员进行教育，并采购可用的支持性护理资源。缺乏训练有素且经验丰富的专业人员以及持续存在的技能差距限制了就业前景和获得优质工作的机会。因此，显然，拥有足够技能的专业人员的可用性对市场增长构成了挑战。
COVID-19 对紫杉烷市场的影响
COVID-19 导致医护人员和普通民众对医疗用品的需求大幅增加，以采取预防措施。这些产品的制造商有机会通过确保市场上个人防护设备的稳定供应来利用医疗用品需求的增长。预计 COVID-19 将对紫杉烷市场产生重大影响。
最新动态
- 2022 年 11 月，Viatris Inc. 和 Biocon Biologics Ltd. 宣布在美国推出可互换的生物仿制药 SEMGLEE（甘精胰岛素-yfgn）注射液（品牌产品）和 Insulin Glargine（甘精胰岛素-yfgn）注射液（无品牌产品），以帮助控制成人和儿童 1 型糖尿病患者以及成人 2 型糖尿病患者的高血糖。这两种生物仿制药均有小瓶和预充笔形式，可与参考品牌 LANTUS（甘精胰岛素）互换，从而可以在药房柜台进行替换。Viatris 致力于改善患者获得可持续、优质和更实惠的医疗保健的机会。这有助于公司扩大其产品组合。
- 2022 年 5 月，仿制药和生物类似药领域的全球领导者 Sandoz 宣布在美国推出其仿制药吡非尼酮，这是首个与 Genentech 的 Esbriet 相当的 AB 级（完全可替代）药物，用于治疗特发性肺纤维化 (IPF) 患者。这种处方口服药可通过专科药房立即提供给患者，符合条件的患者可享受 0 美元自付费用计划。Sandoz 将患者放在首位，扩大了这种罕见疾病患者获得仿制药吡非尼酮的机会，他们将受益于更实惠但同样有效的治疗。这有助于该公司扩大其市场地位和业务。
紫杉烷的应用范围和市场规模
紫杉烷市场根据类型、药物类型、配方、年龄组、应用、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按类型
- 紫杉醇
- 多西他赛
- 卡巴他赛
根据类型，北美紫杉烷市场分为紫杉醇、多西他赛和卡巴他赛。
按应用
- 卵巢癌
- 乳腺癌
- 前列腺癌
- 非小细胞肺癌
- 其他
根据应用，北美紫杉烷市场分为卵巢癌、乳腺癌、前列腺癌、非小细胞肺癌和其他。
按药物类型
- 泛型
- 品牌
根据药物类型，北美紫杉烷市场分为品牌药物和仿制药。
按配方
- 脂质体
- 纳米粒子
- 聚合物胶束
- 其他的
根据配方，北美紫杉烷市场分为脂质体、纳米颗粒、聚合物胶束和其他。
按年龄组
- 成人
- 老年
根据年龄组，北美紫杉烷市场分为成年人和老年人。
按最终用户
- 医院
- 门诊手术中心
- 专科诊所
- 其他的
根据最终用户，北美紫杉烷市场分为医院、门诊手术中心、专科诊所和其他。
按分销渠道
- 直接招标
- 零售销售
根据分销渠道，北美紫杉烷市场分为直接招标、零售销售。
北美紫杉烷市场区域分析
对紫杉烷市场进行分析，并按类型、药物类型、配方、年龄组、应用、最终用户和分销渠道提供市场规模信息。
紫杉烷市场报告涵盖的国家包括美国、加拿大、墨西哥。
2022 年，美国将占据主导地位，因为美国是最大的消费市场，GDP 较高，拥有主要市场参与者。由于药物治疗技术的进步，美国预计将实现增长。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
紫杉烷市场还为您提供每个国家医疗保健行业增长的详细市场分析。此外，它还提供有关医疗保健服务和治疗、监管情景的影响以及紫杉烷市场趋势参数的详细信息。
竞争格局和紫杉烷市场份额分析
紫杉烷市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对紫杉烷药物的关注有关。
涉足紫杉烷市场的主要公司有 Viatris Inc.、Sandoz International GmbH (Novartis 分部)、sanofi-aventis US LLC、Hikma Pharmaceuticals PLC、Pfizer Inc.、Dr. Reddy's Laboratories Ltd.、Taxane Healthcare、Bristol-Myers Squibb Company、Fresenius Kabi AG (Fresenius SE & Co. KGaA 的子公司)、SAMYANG HOLDINGS CORPORATION.、Luye Pharma Group、Elevar Therapeutics、Huiang Pharmaceutical Co Ltd.、Shenzhen Main Luck Phar maceuticals Inc.、Accord Healthcare、Torrent Pharmaceuticals Ltd.、Panacea Biotec、RPG Life Sciences Limited.、Aureate Healthcare、Samarth Life Sciences Pvt. Ltd.、Cipla Inc.、Hetero Healthcare Limited.、AqVida GmbH、Ingenus Pharmaceuticals, LLC 等。
预计主要市场参与者的合并、收购和协议等战略联盟将进一步加速紫杉烷药物的增长。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在紫杉烷市场的影响力，这也为组织的利润增长带来了好处。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、北美与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA TAXANE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL_ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
6.1 CONCLUSION
7 NORTH AMERICA TAXANE MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN INCIDENCE OF CANCER
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS
8.1.4 USE OF REIMBURSEMENT FOR TAXANE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT
8.2.3 RISE IN PRODUCT RECALLS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT
9 NORTH AMERICA TAXANE MARKET, BY TYPE
9.1 OVERVIEW
9.2 PACLITAXEL
9.2.1 BY TYPE
9.2.1.1 SEMI-SYNTHETIC
9.2.1.2 NATURAL
9.2.2 BY STRENGTH
9.2.2.1 100MG
9.2.2.2 200MG
9.2.2.3 250MG
9.2.2.4 30MG
9.2.2.5 260MG
9.2.2.6 300MG
9.3 DOCETAXEL
9.3.1 120MG
9.3.2 80MG
9.3.3 20MG
9.3.4 40MG
9.3.5 60MG
9.4 CABAZITAXEL
9.4.1 60MG
10 NORTH AMERICA TAXANE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BREAST CANCER
10.3 NON-SMALL CELL LUNG CANCER
10.4 PANCREATIC CANCER
10.5 OVARIAN CANCER
10.6 PROSTATE CANCER
10.7 OTHERS
11 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERICS
11.3 BRANDED
12 NORTH AMERICA TAXANE MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 LIPOSOMES
12.3 NANOPARTICLES
12.4 POLYMERIC MICELLES
12.5 OTHERS
13 NORTH AMERICA TAXANE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.2.1 FEMALE
13.2.2 MALE
13.3 GERIATRIC
13.3.1 FEMALE
13.3.2 MALE
14 NORTH AMERICA TAXANE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 AMBULATORY SURGICAL CENTERS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 HOSPITAL PHARMACY
15.2.2 RETAIL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
16 NORTH AMERICA TAXANE MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA TAXANE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 SANOFI-AVENTIS U.S. LLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA )
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 HIKMA PHARMACEUTICALS PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ACCORD HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AQVIDA GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 AUREATE HEALTHCARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 DR. REDDY’S LABORATORIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 ELEVAR THERAPEUTICS
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 HETERO HEALTHCARE LIMITED.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HUIANG PHARMACEUTICAL CO LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 INGENUS PHARMACEUTICALS, LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 LUYE PHARMA GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 PANACEA BIOTEC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 RPG LIFE SCIENCES LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SAMARTH LIFE SCIENCES PVT. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SAMYANG HOLDINGS CORPORATION.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 TORRENT PHARMACEUTICALS LTD
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 TAXANE HEALTHCARE
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 U.S. TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.S. PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 U.S. TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 U.S. TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 57 U.S. TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 U.S. PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 59 U.S. DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 60 U.S. CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 61 U.S. TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 U.S. ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 63 U.S. GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 64 U.S. TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 U.S. TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 U.S. RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 CANADA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 CANADA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 CANADA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 CANADA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 CANADA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 CANADA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 73 CANADA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 74 CANADA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 75 CANADA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 76 CANADA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 77 CANADA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 78 CANADA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 CANADA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 CANADA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 MEXICO TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 MEXICO PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 MEXICO TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 MEXICO TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 MEXICO TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 MEXICO PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 87 MEXICO DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 88 MEXICO CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 89 MEXICO TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 90 MEXICO ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 91 MEXICO GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 92 MEXICO TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 MEXICO TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 MEXICO RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA TAXANE MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA TAXANE MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA TAXANE MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA TAXANE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA TAXANE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA TAXANE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA TAXANE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA TAXANE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA TAXANE MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE NORTH AMERICA TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TAXANE MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TAXANE MARKET
FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020
FIGURE 16 NORTH AMERICA TAXANE MARKET: BY TYPE, 2021
FIGURE 17 NORTH AMERICA TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 NORTH AMERICA TAXANE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA TAXANE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA TAXANE MARKET: BY APPLICATION, 2021
FIGURE 21 NORTH AMERICA TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA TAXANE MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA TAXANE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, 2021
FIGURE 25 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA TAXANE MARKET: BY FORMULATION, 2021
FIGURE 29 NORTH AMERICA TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 NORTH AMERICA TAXANE MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA TAXANE MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, 2021
FIGURE 33 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 34 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 36 NORTH AMERICA TAXANE MARKET: BY END USER, 2021
FIGURE 37 NORTH AMERICA TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 NORTH AMERICA TAXANE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA TAXANE MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA TAXANE MARKET: SNAPSHOT (2021)
FIGURE 45 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2021)
FIGURE 46 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 NORTH AMERICA TAXANE MARKET: BY TYPE (2022-2029)
FIGURE 49 NORTH AMERICA TAXANE MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
